Search
Menu
PI Physik Instrumente - Revolution In Photonics Align ROSLB 3/24

China Medical Technologies Inc.

Facebook X LinkedIn Email
China Medical Technologies Inc. (CMED) of Beijing, and Leica Biosystems, a division of Leica Microsystems of Wetzlar, Germany, will collaborate to develop and market fluorescence in situ hybridization (FISH) kits for the Leica Bond system, an automated staining platform. The companies will develop automated solutions for tissue sample tests on HER-2, EGFR and TOP2A genes, all of which play a role in targeted drug therapy for breast, lung and stomach cancer. They also will work on additional FISH applications. CMED will sell the kits in China, while Leica will have the option to sell them in the rest of the world.
Gentec Electro-Optics Inc   - Measure Your Laser MR


Published: October 2011
Asia-Pacificautomated FISH kitsBiophotonicsbreast cancer drug therapyBusinesscancer therapy drugsChinaChina Medical Technologies Inc.CMEDcytologyEGFR geneEuropeFISH kitsGermanyHER-2 genehistopathologyImagingin vitro diagnosticsLeica BiosystemsLeica BONDLeica Microsystemslung cancer drug therapymicroscopesprenatal applicationsRapidScanstaining platformstomach cancer drug therapytissue sample testsTOP2A gene

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.